Data Sheet 1_Pharmacogenomics-guided therapy for essential hypertension: a multi-center randomized controlled open-label trial.pdf

This study aimed to investigate the prevalence of relevant genetic variants among hypertensive patients in Hunan Province, China, and evaluate the efficacy of genotype-directed vs. clinically guided therapy.</p>Methods<p>A total of 2,702 patients with essential hypertension from 14 hospitals were enrolled and evenly randomized to either a control group receiving standard care or an experimental group receiving pharmacogenomics-tailored medication.

Genetic variants in seven gene loci (ADRB1, CYP2D6, CYP3A5, CACNA1C, CYP2C9, ACE, ADD1) associated with five major drug classes were analyzed. Blood pressure and biochemical parameters were assessed at baseline and 4 weeks post-intervention.</p>Results<p>The frequencies of the risk allele frequencies for ACE, CYP2C9, ADRB1, CYP2D6, CYP3A5, CACNA1C, and ADD1 were 34.3%, 4.8%, 74.8%, 57.3%, 69.8%, 11.9%, and 46.3%, respectively.